# TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

> **NCT04599790** · PHASE2 · COMPLETED · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 30 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** TACE combined with lenvatinib and sintilimab

## Key facts

- **NCT ID:** NCT04599790
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-11-29
- **Final completion:** 2022-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599790, "TACE Combined With Lenvatinib and Sintilimab for Advanced HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04599790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*